Vera Therapeutics Inc Class A VERA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $29.99
- Day Range
- $29.87–31.11
- 52-Week Range
- $23.12–56.01
- Bid/Ask
- $30.69 / $30.80
- Shares Outstanding
- 72.06M
- Market Cap
- $2.22B
- Volume/Avg
- 499,780 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 361
- Website
- https://www.veratx.com
Valuation
|
Metric
|
VERA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.29 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VERA
|
|---|---|
Quick Ratio | 10.41 |
Current Ratio | 10.92 |
Interest Coverage | −55.38 |
Quick Ratio
VERA
Profitability
|
Metric
|
VERA
|
|---|---|
Return on Assets (Normalized) | −58.97% |
Return on Equity (Normalized) | −74.00% |
Return on Invested Capital (Normalized) | −66.46% |
Return on Assets
VERA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|DG!^^q& | LOCK|BQLl | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|XQS@$## | LOCK|T?b?S | $84B | |||
| Moderna Inc
MRNA
| LOCK|zg?CY< | LOCK|>z | $83B | |||
| argenx SE ADR
ARGX
| LOCK|?%gFsy | LOCK|zSw | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|gJ^>YK | LOCK|!! | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!?C!#t | LOCK|<BwVJ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#bXn#<Sx | LOCK|@sp< | $29B | |||
| Incyte Corp
INCY
| LOCK|HJFB@b | LOCK|Sc# | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|?sdy<K | LOCK|>&d | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|mb?D^Pv | LOCK|qMW | $14B |
United States